High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel [2]

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 6, 2002, Pages 632-633

  Abali, Hüseyin ^a   Çelik, Ismail ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAXANE DERIVATIVE;

ADULT; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CASE REPORT; CENTRAL NERVOUS SYSTEM TUMOR; DRUG PENETRATION; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING;

EID: 0036898554     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200212000-00023     Document Type: Letter

References (5)

1. Crivellari D, Pagani O, Veronesi A, et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001;12:353-6.
2. Tsukada Y, Fouad A, Pickren JW, et al. Central nervous system metastasis from breast carcinoma, autopsy study. Cancer 1983;52:2349-54.
3. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-Year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19:602-11.
4. Arndt CA, Balis FM, McCully CL, et al. Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys. Cancer Res 1988;48:2113-5.
5. Crown J, O'Leary M. The taxanes: An update. Lancet 2000;355:1176-8.